The National Institute of Allergy and Infectious Diseases (NIAID) has issued a Broad Agency Announcement (BAA) soliciting proposals for development of products for treatment of radiation exposures resulting from nuclear and radiological attacks.
The BAA seeks organizations with the capabilities to advance the development of candidate medical countermeasures (MCMs) for gastrointestinal acute radiation syndrome (GI-ARS). For this funding activity, it is anticipated that candidate MCMs will enter the evaluation and development pathway at various stages, from early research to post marketing (for drugs or biologics that are already licensed or approved for other indications). Offerors are expected to provide a Statement of Work based on the stage of the candidate and the work that needs to be performed to advance the MCM.
NIAID’s overall goal is development of products for treatment of radiation exposures resulting from nuclear and radiological attacks to the stage where products are eligible for advanced product development by the Biomedical Advanced Research and Development Authority or acquisition under the Project BioShield Act of 2004.
It is anticipated that 2-4 contracts will be awarded for a 3-year period of performance beginning on or about July 15, 2013. NIAID estimates that the average annual total cost will be $1-2 million per contract award per year depending on the length and scope of the project. Further details are available under Solicitation Number: BAA-NIAID-DAIT-NIHAI2012147. The current proposal deadline is November 15, 2012.
Update: The response deadline has been extended to November 29, 2012 due to Superstorm Sandy.
